BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.

BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
复制标题

DOI:
10.1038/sj.bjc.6604181
复制
发表时间:
2008-02-12
影响因子:
8.8
通讯作者:
Klenova, E.
Klenova, E.
中科院分区:
医学1区
文献类型:
--
作者:
D'Arcy, V.;Pore, N.;Docquier, F.;Abdullaev, Z. K.;Chernukhin, I.;Kita, G-X;Rai, S.;Smart, M.;Farrar, D.;Pack, S.;Lobanenkov, V.;Klenova, E.

文献摘要

参考文献

被引文献

相似文献

BORIS(印记位点调节器的兄弟)是转录因子 CTCF 的旁系同源物,是癌症睾丸抗原家族的新成员。本研究的目的如下:(1) 使用免疫组织化学染色、蛋白质印迹和实时 RT-PCR 分析来研究乳腺细胞和肿瘤中的 BORIS 表达,以及 (2) 评估肿瘤中 BORIS 水平与临床/病理参数之间的潜在相关性。在所有 18 个检查的乳腺细胞系中均检测到了 BORIS,但在原代正常乳腺细胞培养物中未检测到。 70.7%(58 例中的 41 例)的乳腺肿瘤中观察到了 BORIS。高水平的 BORIS 与高水平的孕激素受体 (PR) 和雌激素受体 (ER) 相关。 BORIS 在报告基因检测中激活 PR 和 ER 基因启动子的能力进一步证实了 BORIS 和 PR/ER 之间的联系。在高比例的乳腺癌患者中检测到 BORIS 意味着 BORIS 作为乳腺癌分子生物标志物的潜在实际应用。这对于疾病的诊断和 BORIS 的治疗用途可能很重要。 BORIS 激活 RP 和 ER 基因启动子的能力表明 BORIS 可能参与乳腺肿瘤的形成、进展和维持。
BORIS (for brother of the regulator of imprinted sites), a paralogue of the transcription factor, CTCF, is a novel member of the cancer-testis antigen family. The aims of the present study were as follows: (1) to investigate BORIS expression in breast cells and tumours using immunohistochemical staining, western and real-time RT–PCR analyses and (2) assess potential correlation between BORIS levels in tumours with clinical/pathological parameters. BORIS was detected in all 18 inspected breast cell lines, but not in a primary normal breast cell culture. In 70.7% (41 of 58 cases) BORIS was observed in breast tumours. High levels of BORIS correlated with high levels of progesterone receptor (PR) and oestrogen receptor (ER). The link between BORIS and PR/ER was further confirmed by the ability of BORIS to activate the promoters of the PR and ER genes in the reporter assays. Detection of BORIS in a high proportion of breast cancer patients implies potential practical applications of BORIS as a molecular biomarker of breast cancer. This may be important for diagnosis of the condition and for the therapeutic use of BORIS. The ability of BORIS to activate promoters of the RP and ER genes points towards possible involvement of BORIS in the establishment, progression and maintenance of breast tumours.
DOI: 10.1158/0008-5472.can-05-2715
发表时间: 2006-02-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Huggins, GS;Wong, JYY;De Vivo, I
通讯作者: De Vivo, I
DOI: 10.1002/ijc.10644
发表时间: 2002-10-20
影响因子: 6.4
作者:
Barrett, A;Madsen, B;Taylor-Papadimitriou, J
通讯作者: Taylor-Papadimitriou, J
DOI: 10.4049/jimmunol.178.1.566
发表时间: 2007-01-01
影响因子: 4.4
作者:
Ghochikyan, Anahit;Mkrtichyan, Mikayel;Agadjanyan, Michael G.
通讯作者: Agadjanyan, Michael G.
DOI: 10.1158/1078-0432.ccr-05-2731
发表时间: 2006-10-15
影响因子: 11.5
作者:
Darcy, Vivien;Abdullaev, Ziedulla K.;Klenova, Elena
通讯作者: Klenova, Elena
睾丸特异性因子CTCFL与H19印迹控制区甲基化中的蛋白甲基转移酶PRMT7合作。
DOI: 10.1371/journal.pbio.0040355
发表时间: 2006-10
期刊: PLOS BIOLOGY
影响因子: 9.8
作者:
Jelinic, Petar;Stehle, Jean-Christophe;Shaw, Phillip
通讯作者: Shaw, Phillip